SpecificationsSubject areaChemistryMore specific subject areaNatural Products--ToxicogenomicsOrganism/cell line/tissueCD-1 miceSexMaleSequencer or array typeAffymetrix mouse gene chip 1.0 ArrayData formatRaw and Analyzed with RMA and two way ANOVAExperimental factorsComparison of control (SSI) and treatment (100 mg/Kg) with soulatrolide or mammea A/BA + A/BB (3:1) mixtureExperimental featuresRNA was extracted from the liver of mice after 1 week of treatment, converted to cDNA and hybridized to Affymetrix arraysConsentAll animal work was conducted in strict accordance with relevant national and international guidelines. The study protocol IG-2005-13 was approved by the Animal and Ethics Experiment Board of School of Medicine of Universidad Nacional Autónoma de MéxicoSample source locationFacultad de Medicina, Universidad Nacional Autónoma de Mexico, Mexico City, Mexico.

1. Direct link to deposited data {#s0005}
================================

The data is deposited in GEO under accession number [GSE72755](ncbi-geo:GSE72755){#ir0010}: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72755>.

2. Value of the data {#s0010}
====================

-The data provide a toxicogenomics signature of two types of pharmacological active coumarins that could be for comparison in other studies of this kind.-The data provide an insight in the metabolism induced by pharmacological active coumarins.-This data provides the first toxicogenomic analysis on mammea type coumarins particularly mammea A/BA and A/BB, and on tetracyclic coumarins such as soulatrolide.

3. Experimental design, materials and methods {#s0015}
=============================================

3.1. Toxicogenomics assay {#s0020}
-------------------------

A total of 12 male mice (*Mus musculus*) strain CD1 (Charles River), body weight 25 ± 4 g, with an age of two month old, were provided by the School of Medicine of the National University of Mexico (UNAM). The animals were kept under standard conditions in ventilated boxes (12 h light/dark and 27 ± 2 °C) and fed with RatChow™ divided in three groups depending on treatments: 1)Soulatrolide, 2)Mammea (A/BA + A/BB 3:1) and 3) Isotonic Saline Solution 0.9% (control). Treatments were administered orally for 7 days at a dose of 100 mg/Kg/daily [@bb0005]. All animal work was conducted in strict accordance with relevant national and international guidelines. The study protocol IG-2005-13 was approved by the Animal and Ethics Experiment Board of School of Medicine of Universidad Nacional Autónoma de México. Liver of animals was immediately obtained after sacrificed and samples immediately homogenized with PureLink® RNA Mini Kit.The amount of RNA was determined by using Nanodrop®2000 (ThermoScientific, Waltham, MA, USA), integrity of RNA was determined using a Bioanalyzer®(Agilent, Waldbronn, Germany) cDNA synthesis, target hybridization, probe array washing, staining and subsequent probe array scanning were done according to the standard protocol 3′IVT Express Kit User Manual (Affymetrix). Microarray analysis was performed by using Affymetrix Mouse Gene Chip 1.0 Array, using three microarrays per treatment.

3.2. Microarray experiments and data acquisition processing {#s0025}
-----------------------------------------------------------

Signal intensities from each array were analyzed using Partek Genomic Suite 6.4 (Partek Inc., Missouri, USA). Raw intensity probe values were normalized using robust multiarray analysis background correction (RMA). A two way ANOVA was performed to identify differentially expressed genes. Only genes with statistically significant differences in expression levels (p-value \< 0.05) and a fold change criteria of ≥ 1.5and ≤− 1.5 were included in the final set of differentially expressed genes ([Table 1](#t0005){ref-type="table"}).

3.3. Gene ontology (GO) analysis {#s0030}
--------------------------------

The list of genes with significantly changed expression levels for both treatments revealed 46 genes up and 72 downregulated genes; meanwhile, for soulatrolide 665 up and 1077 downregulated genes were used as input lists for the DAVID Functional Annotation Clustering tool [@bb0010]. This open source software provides an enrichment analysis of annotation and gene ontology terms based on a GO: TermFinder. The corrected p-value was obtained by applying Bonferroni correction [@bb0010].
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###### 

Analysis of pathways enriched by coumarins treatments (Soulatrolide 1744 DEG\'s and Mammea A/BA + A/BB-120 DEG\'s).

  ---------------------------------------------------------------------------------------------------------------------------
  Treatment/genes                                    Pathway                                              P-Value     Count
  -------------------------------------------------- ---------------------------------------------------- ----------- -------
  Mammea A/BA + A/BB (3:1)\                          KEGG_PATHWAY:\                                       4.96E-5     8
  Down Regulated Genes\                              00830 Retinol metabolism                                         
  (Fold Change \> 1.5  \< − 1.5; p-value \< 0.05).                                                                    

  KEGG_PATHWAY:\                                     0.00103                                              5           
  00982\                                                                                                              
  Drug metabolism                                                                                                     

  Mammea A/BA + A/BB (3:1)\                          KEGG_PATHWAY\                                        0.005272    4
  Up regulated genes\                                04060:Cytokine--cytokine\                                        
  (fold change \> 1.5  \< − 1.5; P-VALUE \< 0.05).   receptor interaction                                             

  Soulatrolide\                                      KEGG_PATHWAY\                                        3.36E-11    34
  Down regulated genes\                              00980:Metabolism of xenobiotics by cytochrome P450               
  (fold change \> 1.5  \< − 1.5; p-value \< 0.05).                                                                    

  KEGG_PATHWAY\                                      4.94E-10                                             38          
  00982:Drug metabolism                                                                                               

  KEGG_PATHWAY\                                      2.36E-8                                              52          
  00830:Retinol metabolism                                                                                            

  Soulatrolide\                                      KEGG_PATHWAY\                                        3.359E-11   34
  Up regulated genes\                                00980:Metabolism of\                                             
  (Fold change \> 1.5  \< − 1.5; p-value \< 0.05).   xenobiotics by CYP\                                              
                                                     P450                                                             

  KEGG_PATHWAY\                                      4.94E-10                                             38          
  00982:Drug\                                                                                                         
  metabolism                                                                                                          

  KEGG_PATHWAY\                                      2.36E-8                                              52          
  00830:Retinol\                                                                                                      
  metabolism                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------
